To a considerable extent, the acceptance of modeling and simulation (M&S) approaches (beyond traditional PD/PK) inside biopharma remains stuck at a low level and something is needed to get it unstuck—especially among senior management.One idea might be to compile a list of successful projects, successfully updated, in which modeling and simulation had an important or decisive effect, and ti characterize the approach used and quantify the benefits.
Modeling and Simulation Still Need a Push
December 19, 2008